<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The <z:e sem="disease" ids="C0085278" disease_type="Disease or Syndrome" abbrv="">antiphospholipid syndrome</z:e> is defined as the association between the presence of <z:hpo ids='HP_0003613'>antiphospholipid antibodies</z:hpo>, detected as anticardiolipin antibodies and/or <z:e sem="disease" ids="C0024138,C0024141,C0024131,C0409974" disease_type="Disease or Syndrome" abbrv="">lupus</z:e> <z:chebi fb="3" ids="50249">anticoagulant</z:chebi>, and a history of either arterial or <z:hpo ids='HP_0004936'>venous thrombosis</z:hpo> and/or recurrent pregnancy loss </plain></SENT>
<SENT sid="1" pm="."><plain>Because <z:mp ids='MP_0005048'>thrombosis</z:mp> may occur in virtually any organ system, diagnosing the <z:e sem="disease" ids="C0085278" disease_type="Disease or Syndrome" abbrv="">antiphospholipid syndrome</z:e> and taking appropriate anticoagulation measures are important considerations in <z:hpo ids='HP_0000001'>all</z:hpo> medical specialties </plain></SENT>
<SENT sid="2" pm="."><plain><z:hpo ids='HP_0003613'>Antiphospholipid antibody</z:hpo>-associated <z:mp ids='MP_0005048'>thrombosis</z:mp> tends to recur </plain></SENT>
<SENT sid="3" pm="."><plain>Antithrombotic prophylaxis to prevent recurrences is therefore needed </plain></SENT>
<SENT sid="4" pm="."><plain>Prophylaxis in individuals with circulating <z:hpo ids='HP_0003613'>antiphospholipid antibodies</z:hpo> who have no history of <z:mp ids='MP_0005048'>thrombosis</z:mp> is still controversial </plain></SENT>
<SENT sid="5" pm="."><plain>Although direct evidence for a pathogenetic role of <z:hpo ids='HP_0003613'>antiphospholipid antibodies</z:hpo> in the development of <z:mp ids='MP_0005048'>thrombosis</z:mp> is still lacking, recent studies suggest that it is causative rather than coincidental </plain></SENT>
<SENT sid="6" pm="."><plain>New insights on the possible mechanisms leading to <z:mp ids='MP_0005048'>thrombosis</z:mp> were provided by the discovery of the serum cofactor (beta2-GPI), a coagulation inhibitor which is required for binding of anticardiolipin antibodies to <z:chebi fb="0" ids="28494">cardiolipin</z:chebi> </plain></SENT>
<SENT sid="7" pm="."><plain>More recently, patients with <z:hpo ids='HP_0003613'>antiphospholipid antibodies</z:hpo> were found to possess autoantibodies directed against other coagulation factors, including prothrombin, protein C and protein S </plain></SENT>
<SENT sid="8" pm="."><plain>Future studies should clarify whether these different antigenic specificities are associated with particular clinical events and assess the risk of <z:mp ids='MP_0005048'>thrombosis</z:mp> associated with the presence of <z:hpo ids='HP_0003613'>antiphospholipid antibodies</z:hpo> in asymptomatic individuals </plain></SENT>
</text></document>